Pfizer (PFE) Stock Sinks As Market Gains: Here's Why

Pfizer (PFE) ended the recent trading session at $25.35, demonstrating a -1.17% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 0.14%. Elsewhere, the Dow saw an upswing of 0.2%, while the tech-heavy Nasdaq appreciated by 0.27%. The stock of drugmaker has risen by 4.52% in the past month, leading the Medical sector's loss of 1.34% and the S&P 500's gain of 3.97%.The investment community will be paying close attention to the earnings performance of Pfizer in its upcoming release. The company is slated to reveal its earnings on August 5, 2025. The company's upcoming EPS is projected at $0.59, signifying a 1.67% drop compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $13.6 billion, reflecting a 2.36% rise from the equivalent quarter last year. PFE's full-year Zacks Consensus Estimates are calling for earnings of $3.05 per share and revenue of $63.4 billion. These results would represent year-over-year changes of -1.93% and -0.36%, respectively. Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Pfizer. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability. Our research shows that these estimate changes are directly correlated with near-term stock prices. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system. The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.54% lower. Pfizer is currently sporting a Zacks Rank of #3 (Hold). Looking at its valuation, Pfizer is holding a Forward P/E ratio of 8.41. This denotes a discount relative to the industry average Forward P/E of 13.66. One should further note that PFE currently holds a PEG ratio of 0.93. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Large Cap Pharmaceuticals was holding an average PEG ratio of 1.27 at yesterday's closing price. The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 25, this industry ranks in the top 11% of all industries, numbering over 250. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. You can find more information on all of these metrics, and much more, on Zacks.com. 5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They includeStock #1: A Disruptive Force with Notable Growth and ResilienceStock #2: Bullish Signs Signaling to Buy the DipStock #3: One of the Most Compelling Investments in the MarketStock #4: Leader In a Red-Hot Industry Poised for GrowthStock #5: Modern Omni-Channel Platform Coiled to SpringMost of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.Download Atomic Opportunity: Nuclear Energy's Comeback free today.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks